Oruka Therapeutics, Inc. (ORKA) stock analysis
In our weekly check, Oruka Therapeutics, Inc. is graded F (A to F). Of 17 checks on debt, profit, cash flow and trend: 6 pass, warnings: 2, red flags: 9.
About Oruka Therapeutics, Inc.
Oruka Therapeutics, Inc. is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as ORKA.
What our checks show for ORKA
Red flags
- Weak EPS forecast
- Earnings per share fell 33.7% a year over the last 3 years.
- The company has no revenue yet.
- Free cash flow is negative and the company has no revenue yet: it lives on its cash and new funding.
- The price swings a lot: 65.5% annual volatility. Expect large ups and downs.
- The stock has fallen as much as 100% from a peak. Would you have held through that?
- The share count grew by 216% in 2 years: each shareholder owns a smaller slice.
- Return on capital (ROCE) is zero or negative: the business does not earn on the money put into it.
- Free cash flow is negative, so no cash is left over to cover pay in shares.
Warning signs
- Operating cash flow is negative while the company reports a profit: the profit does not arrive as cash.
- The stock is still below its previous peak.
Strengths
- Debt is low: 0x equity.
- Beta -0.39: the stock usually moves less than the market.
Similar companies
IMVT · TXG · KOD · TWST · AXSM · ARWR
Questions
What grade does Oruka Therapeutics, Inc. (ORKA) have?
In our weekly check, Oruka Therapeutics, Inc. is graded F (A to F). Of 17 checks on debt, profit, cash flow and trend: 6 pass, warnings: 2, red flags: 9. The grade is a risk check, not a buy or sell recommendation.
What are the main risks of ORKA stock?
This week's biggest flags for Oruka Therapeutics, Inc.: Weak EPS forecast, Weak EPS growth, Thin margins. In total 11 of 17 checks show a warning or a red flag.
What does Oruka Therapeutics, Inc. do?
Oruka Therapeutics, Inc. is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as ORKA.
The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.
Updated 2026-11-14
Open the full analysis